T. Cigler

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
T Cigler, T. Cigler, Tessa Cigler
Publication record
81 papers · 1,632 citations · H-index 21

PAPERS

WBC Growth Factors: ASCO Guideline Update.
20260 citationsauthor #14
Exploring the “obesity paradox” in triple negative breast cancer patients receiving neoadjuvant immunotherapy.
20250 citationsauthor #12
Abstract PO5-08-11: Genetic Landscape of Early Breast Cancer in an Ashkenazi Jewish Cohort
20240 citationsauthor #6
[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases.
20244 citationsauthor #7
Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer.
20230 citationsauthor #4
Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer
202210 citationsauthor #5
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer
202164 citationsauthor #9
Fluoroestradiol ( FES ) PET / CT with dedicated brain acquisition in differentiating brain metastases from post treatment change in estrogen receptor-positive breast cancer
20210 citationsauthor #4
Benefit of Adjuvant Chemotherapy in Node-Negative T1a Versus T1b and T1c Triple Negative Breast Cancer
20211 citationsauthor #5
Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer
202110 citationsauthor #9
Utility of [18F]-fluoroestradiol (FES) PET/CT with dedicated brain acquisition in differentiating brain metastases from posttreatment change in estrogen receptor-positive breast cancer
20218 citationsauthor #4
Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
202064 citationsauthor #7
Abstract P1-19-32: Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+ metastatic breast cancer (MBC)
20200 citationsauthor #5
Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases
202013 citationsauthor #9
LONGITUDINAL OVARIAN RESERVE CHANGES IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT CHEMOTHERAPY OR TAMOXIFEN-ALONE
20201 citationsauthor #6
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer
202036 citationsauthor #6
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic
202020 citationsauthor #11
Abstract PD6-06: Impact ofBRCAmutations on chemotherapy-induced loss of ovarian reserve: A prospective longitudinal study
20192 citationsauthor #7
Abstract P1-17-04: Long-term safety follow-up of patients with early stage breast cancer treated with scalp cooling on the Dignitana scalp cooling trial
20191 citationsauthor #9
Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.
201960 citationsauthor #13
Abstract PD9-07: A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with high risk breast cancer (BC): Role of collagen processing and tumor microenvironment
20190 citationsauthor #7
Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study
201947 citationsauthor #14
Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus
20186 citationsauthor #3
Abstract P1-10-02: A phase II study of copper-depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence: Updated results
20181 citationsauthor #6
Abstract P1-10-10: Tumor infiltrating lymphocytes (TILS) among high risk for recurrence breast cancer patients treated with tetrathimolybdate (TM)
20180 citationsauthor #4
Novel and Previously Reported Single-Nucleotide Polymorphisms in the Human 5-HT1B Receptor Gene
20180 citationsauthor #1
Elevated 70kDa heat shock protein (hsp70) and autophagy levels in peripheral blood mononuclear cells (PBMCs) in women with a malignant breast mass.
20180 citationsauthor #7
Breast cancer survivorship care plan: Patient satisfaction with a web-based application.
20182 citationsauthor #6
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
201791 citationsauthor #6
Facilitating informed decisions about breast cancer screening: development and evaluation of a web-based decision aid for women in their 40s
201729 citationsauthor #4
A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence: Updated results.
20176 citationsauthor #5
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer
2017150 citationsauthor #13
Abstract P5-11-17: Body image in women with breast cancer using a scalp cooling system to reduce chemotherapy induced alopecia
20171 citationsauthor #1
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases
2016164 citationsauthor #9
Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
20160 citationsauthor #7
Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia.
201512 citationsauthor #11
Abstract P1-09-06: A prospective longitudinal study of the impact of breast cancer treatment with adjuvant chemotherapy or tamoxifen alone on ovarian reserve
20150 citationsauthor #5
Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy.
201545 citationsauthor #1
Altering the tumor microenvironment: A phase II study of copper depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence.
20153 citationsauthor #4
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
201531 citationsauthor #13
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
2015159 citationsauthor #7
Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
201567 citationsauthor #9
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
20159 citationsauthor #7
The impact of adjuvant breast cancer (BC) chemotherapy on ovarian reserve and menses.
20152 citationsauthor #5
Abstract P3-08-04: Aspirin and breast cancer risk for BRCA1 and BRCA2 mutation carriers
20150 citationsauthor #9
Impact of oncotype DX recurrence score in the management of breast cancer cases.
201420 citationsauthor #6
Abstract CT309: Influencing the tumor microenvironment: A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence
20140 citationsauthor #5
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
201419 citationsauthor #7
Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer
201424 citationsauthor #6
A prospective longitudinal study of the impact of breast cancer chemotherapy on ovarian reserve: do individuals have differing susceptibilities?
20140 citationsauthor #6
Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients
201429 citationsauthor #7
Hypovitaminosis D is a Predictor of Aromatase Inhibitor Musculoskeletal Symptoms
201421 citationsauthor #2
Abstract P2-16-05: Efficacy of ABT-888 (veliparib) in patients with BRCA-associated breast cancer
20132 citationsauthor #7
Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.
201320 citationsauthor #7
Abstract P6-05-06: Association of HER2/neu single nucleotide polymorphism with trastuzumab-related cardiotoxicity
20130 citationsauthor #10
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.
201387 citationsauthor #6
Efficacy of scalp cryotherapy in preventing alopecia among patients with breast cancer patients receiving adjuvant docetaxel and cyclophosphamide.
20130 citationsauthor #1
Abstract P6-10-01: A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study
201216 citationsauthor #7
Abstract P6-11-04: Targeting the tumor microenvironment: tetrathiomolybdate decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.
20120 citationsauthor #6
ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.
201212 citationsauthor #3
A new paradigm for mechanobiological mechanisms in tumor metastasis.
201252 citationsauthor #3
Incremental increase in VEGFR1+ hematopoietic progenitor cells and VEGFR2+ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients
201230 citationsauthor #7
Abstract 2699: Phase II study evaluating the effect of tetrathiomolybdate on circulating endothelial progenitor cells in patients with high risk for breast cancer recurrence
20120 citationsauthor #8
Abstract P1-15-07: Ixabepilone-associated peripheral neuropathy in metastatic breast cancer patients and its effects on the ultrastructure of neurons
20120 citationsauthor #4
The ixabepilone eribulin mesylate in the treatment of metastatic breast cancer
20120 citationsauthor #2
Defining the aromatase inhibitor musculoskeletal syndrome: A prospective study
201237 citationsauthor #2
The effect of tetrathiomolybdate on endothelial progenitor cells in patients at high risk for breast cancer recurrence.
20110 citationsauthor #8
Abstract 4720: Incremental increase in VEGFR1+ and VEGFR2+ hemangiogenic progenitor cells predict relapse and tumor response in breast cancer (BC) patients
20110 citationsauthor #7
A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy.
20111 citationsauthor #1
Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853.
20113 citationsauthor #7
Abstract P3-15-06: No Correlation between Endocrine Symptoms and Musculoskeletal Symptoms in Women Receiving Adjuvant Aromatase Inhibitor Therapy
20100 citationsauthor #1
Eribulin mesylate for the treatment of breast cancer
201025 citationsauthor #1
Abstract P2-16-14: The Effect of Tetrathiomolybdate (TM) on Circulating Endothelial Progenitor Cells in Women at Moderate to High Risk of BC Recurrence
20101 citationsauthor #5
The effect of tetrathiomolybdate on circulating endothelial progenitor cells in patients with breast cancer at high risk of recurrence.
20091 citationsauthor #5
A Phase II Trial Tetrathiomolybdate (TM), a Copper Depleting Compound, and Its Effect on Circulating Endothelial Progenitor Cells (EPCs) in Patients with Breast Cancer (BC) at High Risk of Recurrence.
20091 citationsauthor #4
Poisoning Associated with Ingestion of Redroot Pigweed (Amaranthus retroflexus) in Cattle – Case Report
20086 citationsauthor #4
Integrating epothilones into the treatment of patients with metastatic breast cancer: clinical perspectives on incorporating recent data in the practice setting.
20084 citationsauthor #1
Breast Cancer Adjuvant Endocrine Therapy
200716 citationsauthor #1
Aromatase inhibitor withdrawal response in metastatic breast cancer.
200613 citationsauthor #1
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
200576 citationsauthor #9
Incidence of ovarian cancer in BRCA-negative hereditary breast cancer families.
20040 citationsauthor #2

TIMELINE

2004 0 citations

2005 76 citations

2006 13 citations

2007 16 citations

2008 10 citations

2009 2 citations

2010 26 citations

2011 4 citations

2012 147 citations

2013 109 citations

2014 113 citations

2015 328 citations

2016 164 citations

2017 277 citations

2018 9 citations

2019 110 citations

2020 134 citations

2021 83 citations

2022 10 citations

2023 0 citations

2024 4 citations

2025 0 citations

2026 0 citations

T. Cigler

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT